clinical trials of pandemic vaccines: key issues john treanor university of rochester rochester, ny
TRANSCRIPT
![Page 1: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/1.jpg)
Clinical Trials of Pandemic Vaccines: Key Issues
John Treanor
University of Rochester
Rochester, NY
![Page 2: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/2.jpg)
Inactivated vaccine approach
• Proven technology - Used successfully in 1957 and 1968
- Abundant efficacy data in both pandemic and interpandemic years
- Very safe, with large safety database
• Manufacturing capacity exists in potentially large scale
• Licensing would be relatively straight-forward
![Page 3: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/3.jpg)
Inactivated vaccine approach
• Unlikely to induce mucosal immunity - May be less effective in preventing spread
• Protection may be strain specific - Little if any cellular immune response
• Requires multiple doses • Manufacturing capacity limited by availability of eggs and capacity for expansion limited
- Cell culture strategies might circumvent this problem
![Page 4: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/4.jpg)
Recent clinical evaluations of potential pandemic viruses
• Duck Singapore/97 (H5N3) as a vaccine for Hong Kong/97 • Recombinant, baculovirus-expressed HA of A/Hong Kong/156/97 (H5) • Whole virion A/Singapore/1/57 (H2N2) and A/Hong Kong/1073/99 (H9N2) • Whole virion and subunit A/Hong Kong/1073 (H9N2)
![Page 5: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/5.jpg)
Egg-grown Duck/Singapore
No adjuvant MF59 adjuvant
100 100 7.5 ug HA
15 ug HA
80 80 30 ug HA
60 60
40 40
20 20
0 0
0 21 42 0 21 42
Study day Study day
Nicholson et al Lancet 357:1937, 2001
![Page 6: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/6.jpg)
Egg-grown Duck/Singapore
Duck Singapore Hong Kong
100 100 7.5 ug HA
15 ug HA
80 80 30 ug HA
60 60
40 40
20 20
0 0
0 21 42 0 21 42
Study day Study day
Nicholson et al Lancet 357:1937, 2001
![Page 7: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/7.jpg)
Reimmunization with Duck/Singapore
300
250
200
150
100
50
0
MF59
Stephenson et al, Vaccine 21:1687, 2003
Base
Day 42
16 mo
Day 21
Plain
![Page 8: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/8.jpg)
Key issues [1]
• Development of standardized, validated surrogate markers of protection
• Responses to inactivated vaccines may be very strain specific - evaluation of strategies to broaden responses
• Adjuvants should be evaluated. Ratio of antigen to adjuvant may be important
• Pre-pandemic priming dose with heterologous variants should be explored
• Dose responses relationships may not be obvious
![Page 9: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/9.jpg)
Recombinant rHA H5 Vaccine
Insect cell expressing
rHA
RBCs
Purified rHA H5 SDS-PAGE
![Page 10: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/10.jpg)
Phase I evaluation of rH5
• Randomized to interval between doses (21, 28, or 42 days) and then to dose groups (90 ug, 45 ug, 25 ug, 90/10 ug, placebo) - Total of 15 groups
• Vaccine or placebo administered in total of 1 mL by i.m. injection
• Sera before and 14 days after dose 1, and before and 7, 14, 21, and 28 days after dose 2
![Page 11: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/11.jpg)
![Page 12: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/12.jpg)
![Page 13: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/13.jpg)
![Page 14: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/14.jpg)
![Page 15: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/15.jpg)
![Page 16: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/16.jpg)
![Page 17: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/17.jpg)
![Page 18: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/18.jpg)
![Page 19: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/19.jpg)
![Page 20: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/20.jpg)
![Page 21: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/21.jpg)
![Page 22: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/22.jpg)
![Page 23: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/23.jpg)
![Page 24: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/24.jpg)
![Page 25: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/25.jpg)
![Page 26: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/26.jpg)
![Page 27: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/27.jpg)
![Page 28: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/28.jpg)
![Page 29: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/29.jpg)
![Page 30: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/30.jpg)
![Page 31: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/31.jpg)
![Page 32: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/32.jpg)
![Page 33: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/33.jpg)
![Page 34: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/34.jpg)
![Page 35: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/35.jpg)
![Page 36: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/36.jpg)
![Page 37: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/37.jpg)
![Page 38: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/38.jpg)
![Page 39: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/39.jpg)
![Page 40: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/40.jpg)
![Page 41: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/41.jpg)
![Page 42: Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY](https://reader035.vdocument.in/reader035/viewer/2022062309/5697bfa91a28abf838c99e2e/html5/thumbnails/42.jpg)